Skip to main content
SpringerLink
Log in

NICE recommends dabrafenib for melanoma . . .

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. NICE recommends another new skin cancer drug. Media Release : 21 Oct 2014. Available from: URL: http://www.nice.org.uk

  2. NICE. NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack. Media Release : 22 Oct 2014. Available from: URL: http://www.nice.org.uk

  3. NICE. NICE recommends dabigatran (Pradaxa) for treating and preventing potentially fatal blood clots. Media Release : 31 Oct 2014. Available from: URL: http://www.nice.org.uk

  4. NICE. NICE proposes to recommend another new drug for people with lymphocytic leukaemia. Media Release : 4 Nov 2014. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE recommends dabrafenib for melanoma . . .. PharmacoEcon Outcomes News 715, 33 (2014). https://doi.org/10.1007/s40274-014-1691-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1691-4

Search

Navigation